Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.16
DRAD's Cash-to-Debt is ranked lower than
88% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 1.84 vs. DRAD: 0.16 )
Ranked among companies with meaningful Cash-to-Debt only.
DRAD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16  Med: N/A Max: No Debt
Current: 0.16
Equity-to-Asset 0.61
DRAD's Equity-to-Asset is ranked higher than
50% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. DRAD: 0.61 )
Ranked among companies with meaningful Equity-to-Asset only.
DRAD' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.99  Med: 0.81 Max: 0.85
Current: 0.61
-1.99
0.85
Interest Coverage 1.53
DRAD's Interest Coverage is ranked lower than
96% of the 228 Companies
in the Global Medical Devices industry.

( Industry Median: 83.04 vs. DRAD: 1.53 )
Ranked among companies with meaningful Interest Coverage only.
DRAD' s Interest Coverage Range Over the Past 10 Years
Min: 1.53  Med: 11.4 Max: No Debt
Current: 1.53
Piotroski F-Score: 4
Altman Z-Score: 1.52
Beneish M-Score: -1.95
WACC vs ROIC
21.34%
19.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 1.92
DRAD's Operating Margin % is ranked lower than
55% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. DRAD: 1.92 )
Ranked among companies with meaningful Operating Margin % only.
DRAD' s Operating Margin % Range Over the Past 10 Years
Min: -11.73  Med: -5.19 Max: 4.56
Current: 1.92
-11.73
4.56
Net Margin % 11.83
DRAD's Net Margin % is ranked higher than
81% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. DRAD: 11.83 )
Ranked among companies with meaningful Net Margin % only.
DRAD' s Net Margin % Range Over the Past 10 Years
Min: -11.06  Med: -4.04 Max: 35.58
Current: 11.83
-11.06
35.58
ROE % 21.41
DRAD's ROE % is ranked higher than
90% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: 3.48 vs. DRAD: 21.41 )
Ranked among companies with meaningful ROE % only.
DRAD' s ROE % Range Over the Past 10 Years
Min: -13.31  Med: -5.16 Max: 49.86
Current: 21.41
-13.31
49.86
ROA % 14.02
DRAD's ROA % is ranked higher than
93% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 0.81 vs. DRAD: 14.02 )
Ranked among companies with meaningful ROA % only.
DRAD' s ROA % Range Over the Past 10 Years
Min: -11.19  Med: -4.26 Max: 40.82
Current: 14.02
-11.19
40.82
ROC (Joel Greenblatt) % 6.79
DRAD's ROC (Joel Greenblatt) % is ranked higher than
50% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 7.00 vs. DRAD: 6.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DRAD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -72.13  Med: -23.36 Max: 34.95
Current: 6.79
-72.13
34.95
3-Year Revenue Growth Rate 5.60
DRAD's 3-Year Revenue Growth Rate is ranked higher than
56% of the 228 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. DRAD: 5.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DRAD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -90.7  Med: -4.9 Max: 35.4
Current: 5.6
-90.7
35.4
» DRAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

DRAD Guru Trades in Q1 2016

Jim Simons 924,200 sh (-0.22%)
» More
Q2 2016

DRAD Guru Trades in Q2 2016

Jim Simons 902,800 sh (-2.32%)
» More
Q3 2016

DRAD Guru Trades in Q3 2016

Jim Simons 863,300 sh (-4.38%)
» More
Q4 2016

DRAD Guru Trades in Q4 2016

Jim Simons 856,100 sh (-0.83%)
» More
» Details

Insider Trades

Latest Guru Trades with DRAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NAS:NVCN, NAS:FONR, NAS:MSON, NAS:EDAP, NAS:CGNT, NAS:ACRX, OTCPK:TITXF, NAS:SPAN, OTCPK:AVMXF, NAS:VIVE, OTCPK:BTCY, NAS:MGCD, AMEX:ELMD, OTCPK:PHMZF, NAS:RWLK, OTCPK:RMSL, NAS:IRIX, OTCPK:DIZTF, OTCPK:VICA, NAS:KOOL » details
Traded in other countries:FDV.Germany,
Digirad Corp provides nuclear cardiology imaging and ultrasound imaging services & cardiac event monitoring services. It also sells medical diagnostic imaging systems.

Digirad Corp was incorporated in Delaware in 1997. The Company is a developer and manufacturer of medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications. The business is organized into two reportable segments: Digirad Imaging Solutions (DIS) and Diagnostic Imaging. It is a provider of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers through Digirad Imaging Solutions ("DIS") business segment. The Company sells medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products it sells through its Diagnostic Imaging segment. The target market for its products and services is comprised of cardiologists, internal medicine physicians, family practice physicians, and hospitals in the United States that perform or could perform nuclear and ultrasound diagnostic imaging procedures. The Company sells a line of nuclear imaging cameras for nuclear cardiology and general nuclear medicine applications. Its cameras are used in hospitals, imaging centers, physician offices and by mobile service providers. Its product Ergo large-field-of-view imaging system is targeted to hospitals with multi-camera general nuclear medicine departments, academic centers, pediatric hospitals, regional trauma centers, women's health centers, and cancer centers. Its Cardius XACT SPECT/CT system features a triple-head design and a low dose volume CT attenuation correction methodology, making it possible to perform studies faster with greater interpretation diagnostic confidence. It uses variety of materials, metals and mechanical and electrical components for production of its products. The Company maintain two sales organizations, which operate independently but in cooperation with each other: Diagnostic Imaging sales and DIS sales. The Company's operations comply with an array of federal and state laws and regulations.

Ratios

vs
industry
vs
history
PE Ratio 8.08
DRAD's PE Ratio is ranked higher than
92% of the 157 Companies
in the Global Medical Devices industry.

( Industry Median: 27.24 vs. DRAD: 8.08 )
Ranked among companies with meaningful PE Ratio only.
DRAD' s PE Ratio Range Over the Past 10 Years
Min: 2.94  Med: 19.09 Max: 192
Current: 8.08
2.94
192
PE Ratio without NRI 8.08
DRAD's PE Ratio without NRI is ranked higher than
93% of the 157 Companies
in the Global Medical Devices industry.

( Industry Median: 28.18 vs. DRAD: 8.08 )
Ranked among companies with meaningful PE Ratio without NRI only.
DRAD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 2.94  Med: 19.09 Max: 192
Current: 8.08
2.94
192
Price-to-Owner-Earnings 24.63
DRAD's Price-to-Owner-Earnings is ranked higher than
66% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 32.45 vs. DRAD: 24.63 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DRAD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.7  Med: 21.34 Max: 51.02
Current: 24.63
0.7
51.02
PB Ratio 1.61
DRAD's PB Ratio is ranked higher than
74% of the 250 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. DRAD: 1.61 )
Ranked among companies with meaningful PB Ratio only.
DRAD' s PB Ratio Range Over the Past 10 Years
Min: 0.19  Med: 1.22 Max: 2.66
Current: 1.61
0.19
2.66
PS Ratio 0.97
DRAD's PS Ratio is ranked higher than
81% of the 252 Companies
in the Global Medical Devices industry.

( Industry Median: 3.24 vs. DRAD: 0.97 )
Ranked among companies with meaningful PS Ratio only.
DRAD' s PS Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.9 Max: 2.1
Current: 0.97
0.12
2.1
Price-to-Free-Cash-Flow 30.70
DRAD's Price-to-Free-Cash-Flow is ranked lower than
53% of the 102 Companies
in the Global Medical Devices industry.

( Industry Median: 29.41 vs. DRAD: 30.70 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DRAD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.95  Med: 26.86 Max: 168.89
Current: 30.7
4.95
168.89
Price-to-Operating-Cash-Flow 13.74
DRAD's Price-to-Operating-Cash-Flow is ranked higher than
72% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 20.17 vs. DRAD: 13.74 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DRAD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.5  Med: 17.41 Max: 401.67
Current: 13.74
3.5
401.67
EV-to-EBIT 68.32
DRAD's EV-to-EBIT is ranked lower than
91% of the 137 Companies
in the Global Medical Devices industry.

( Industry Median: 21.56 vs. DRAD: 68.32 )
Ranked among companies with meaningful EV-to-EBIT only.
DRAD' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.1  Med: -2.1 Max: 203.1
Current: 68.32
-24.1
203.1
EV-to-EBITDA 12.48
DRAD's EV-to-EBITDA is ranked higher than
63% of the 142 Companies
in the Global Medical Devices industry.

( Industry Median: 16.07 vs. DRAD: 12.48 )
Ranked among companies with meaningful EV-to-EBITDA only.
DRAD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -126.6  Med: 5 Max: 161
Current: 12.48
-126.6
161
Shiller PE Ratio 89.03
DRAD's Shiller PE Ratio is ranked lower than
80% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 49.99 vs. DRAD: 89.03 )
Ranked among companies with meaningful Shiller PE Ratio only.
DRAD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 70  Med: 94.07 Max: 194.33
Current: 89.03
70
194.33
Current Ratio 1.14
DRAD's Current Ratio is ranked lower than
83% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 2.24 vs. DRAD: 1.14 )
Ranked among companies with meaningful Current Ratio only.
DRAD' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 4.48 Max: 5.53
Current: 1.14
1.03
5.53
Quick Ratio 0.89
DRAD's Quick Ratio is ranked lower than
80% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.64 vs. DRAD: 0.89 )
Ranked among companies with meaningful Quick Ratio only.
DRAD' s Quick Ratio Range Over the Past 10 Years
Min: 0.88  Med: 3.94 Max: 4.82
Current: 0.89
0.88
4.82
Days Inventory 23.59
DRAD's Days Inventory is ranked higher than
93% of the 246 Companies
in the Global Medical Devices industry.

( Industry Median: 125.61 vs. DRAD: 23.59 )
Ranked among companies with meaningful Days Inventory only.
DRAD' s Days Inventory Range Over the Past 10 Years
Min: 23.59  Med: 40.36 Max: 54.41
Current: 23.59
23.59
54.41
Days Sales Outstanding 45.29
DRAD's Days Sales Outstanding is ranked higher than
81% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. DRAD: 45.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
DRAD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.23  Med: 42.24 Max: 48.9
Current: 45.29
38.23
48.9
Days Payable 30.22
DRAD's Days Payable is ranked lower than
79% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. DRAD: 30.22 )
Ranked among companies with meaningful Days Payable only.
DRAD' s Days Payable Range Over the Past 10 Years
Min: 6.32  Med: 13.32 Max: 30.22
Current: 30.22
6.32
30.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.81
DRAD's Dividend Yield % is ranked higher than
92% of the 189 Companies
in the Global Medical Devices industry.

( Industry Median: 1.74 vs. DRAD: 3.81 )
Ranked among companies with meaningful Dividend Yield % only.
DRAD' s Dividend Yield % Range Over the Past 10 Years
Min: 1.3  Med: 4.08 Max: 5.45
Current: 3.81
1.3
5.45
Dividend Payout Ratio 0.31
DRAD's Dividend Payout Ratio is ranked higher than
77% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 0.42 vs. DRAD: 0.31 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DRAD' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.18  Med: 1.54 Max: 5
Current: 0.31
0.18
5
Forward Dividend Yield % 3.70
DRAD's Forward Dividend Yield % is ranked higher than
93% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 1.81 vs. DRAD: 3.70 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.80
DRAD's 5-Year Yield-on-Cost % is ranked higher than
83% of the 225 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. DRAD: 3.80 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DRAD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.3  Med: 4.08 Max: 5.45
Current: 3.8
1.3
5.45
3-Year Average Share Buyback Ratio -0.50
DRAD's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. DRAD: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DRAD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1344.4  Med: -0.5 Max: 0.6
Current: -0.5
-1344.4
0.6

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 2.25
DRAD's Price-to-Tangible-Book is ranked higher than
70% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 4.05 vs. DRAD: 2.25 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
DRAD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.23  Med: 1.41 Max: 3.01
Current: 2.25
0.23
3.01
Price-to-Intrinsic-Value-Projected-FCF 1.46
DRAD's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
71% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. DRAD: 1.46 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DRAD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.06  Med: 2.05 Max: 114
Current: 1.46
0.06
114
Price-to-Median-PS-Value 1.05
DRAD's Price-to-Median-PS-Value is ranked higher than
52% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. DRAD: 1.05 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DRAD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 1.03 Max: 2.12
Current: 1.05
0.02
2.12
Price-to-Graham-Number 0.90
DRAD's Price-to-Graham-Number is ranked higher than
89% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. DRAD: 0.90 )
Ranked among companies with meaningful Price-to-Graham-Number only.
DRAD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.47  Med: 1.57 Max: 4.16
Current: 0.9
0.47
4.16
Earnings Yield (Greenblatt) % 1.50
DRAD's Earnings Yield (Greenblatt) % is ranked higher than
50% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. DRAD: 1.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DRAD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.5  Med: 4.4 Max: 475
Current: 1.5
0.5
475

More Statistics

Revenue (TTM) (Mil) $109.9
EPS (TTM) $ 0.65
Beta2.36
Short Percentage of Float0.39%
52-Week Range $4.15 - 6.15
Shares Outstanding (Mil)19.89
» More Articles for DRAD

Headlines

Articles On GuruFocus.com
Top 3 Insider Buys Highlighted by Energy Companies Jul 12 2013 
DRAD Directors Increase Their Stake in the Medical Supply Company Apr 25 2013 
Expansion Initiates Insider Buying for NTS Apr 11 2013 
Digirad Corp. Reports Operating Results (10-K/A) Jul 30 2010 
Digirad Corp. Reports Operating Results (10-Q) Jul 29 2010 
Digirad Corp. Reports Operating Results (10-Q) Apr 29 2010 
Digirad Corporation Q3 2009 update Oct 29 2009 
Miguel Barbosa Interviews Famous Blogger, Greenbackd! Oct 29 2009 
Digirad Corp. Reports Operating Results (10-Q) Oct 22 2009 

More From Other Websites
DIGIRAD CORP Files SEC form 8-K, Change in Directors or Principal Officers Feb 28 2017
DIGIRAD CORP Files SEC form 10-K, Annual Report Feb 28 2017
Digirad Corporation to Present at the 29th Annual ROTH Conference on March 14, 2017 Feb 28 2017
Digirad Corporation (DRAD) Looks Good: Stock Jumps 10% Feb 27 2017
Q4 2016 Digirad Corp Earnings Release - Before Market Open Feb 24 2017
Digirad posts 4Q profit Feb 24 2017
Digirad posts 4Q profit Feb 24 2017
DIGIRAD CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 24 2017
Digirad Corporation Reports Financial Results for the Fourth Quarter and Twelve Months ended... Feb 24 2017
Digirad Corporation to Release 2016 Fourth Quarter and Year-End Financial Results on February 24,... Feb 15 2017
Digirad Corporation Announces Quarterly Dividend of $0.05 Per Share Jan 31 2017
ETFs with exposure to Digirad Corp. : December 27, 2016 Dec 27 2016
Digirad Corporation (DRAD): Are Hedge Funds Right About This Stock? Dec 14 2016
ETFs with exposure to Digirad Corp. : December 8, 2016 Dec 08 2016
DIGIRAD CORP Financials Nov 04 2016
DIGIRAD CORP Files SEC form 10-Q, Quarterly Report Oct 31 2016
ETF’s with exposure to Digirad Corp. : October 31, 2016 Oct 31 2016
Digirad Corp. :DRAD-US: Earnings Analysis: Q3, 2016 By the Numbers : October 31, 2016 Oct 31 2016
Digirad Corporation Reports Financial Results for the Third Quarter and Nine Months ended September... Oct 28 2016
DIGIRAD CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)